Your browser doesn't support javascript.
Omicron's binding to sotrovimab, casirivimab, imdevimab, CR3022, and sera from previously infected or vaccinated individuals.
Mader, Anna-Lena; Tydykov, Leonid; Glück, Vivian; Bertok, Manuela; Weidlich, Tanja; Gottwald, Christine; Stefl, Alexa; Vogel, Matthias; Plentz, Annelie; Köstler, Josef; Salzberger, Bernd; Wenzel, Jürgen J; Niller, Hans Helmut; Jantsch, Jonathan; Wagner, Ralf; Schmidt, Barbara; Glück, Thomas; Gessner, André; Peterhoff, David.
  • Mader AL; Institute for Clinical Microbiology and Hygiene, University Hospital Regensburg, 93053 Regensburg, Germany.
  • Tydykov L; Institute for Clinical Microbiology and Hygiene, University Hospital Regensburg, 93053 Regensburg, Germany.
  • Glück V; Institute for Clinical Microbiology and Hygiene, University Hospital Regensburg, 93053 Regensburg, Germany.
  • Bertok M; Kliniken Südostbayern AG, Klinikum Traunstein, 83278 Traunstein, Germany.
  • Weidlich T; Kliniken Südostbayern AG, Klinikum Traunstein, 83278 Traunstein, Germany.
  • Gottwald C; Kliniken Südostbayern AG, Klinikum Traunstein, 83278 Traunstein, Germany.
  • Stefl A; Institute for Clinical Microbiology and Hygiene, University Hospital Regensburg, 93053 Regensburg, Germany.
  • Vogel M; Institute for Clinical Microbiology and Hygiene, University Hospital Regensburg, 93053 Regensburg, Germany.
  • Plentz A; Institute for Clinical Microbiology and Hygiene, University Hospital Regensburg, 93053 Regensburg, Germany.
  • Köstler J; Institute for Clinical Microbiology and Hygiene, University Hospital Regensburg, 93053 Regensburg, Germany.
  • Salzberger B; Department for Infection Control and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany.
  • Wenzel JJ; Institute for Medical Microbiology and Hygiene, University of Regensburg, 93040 Regensburg, Germany.
  • Niller HH; Institute for Medical Microbiology and Hygiene, University of Regensburg, 93040 Regensburg, Germany.
  • Jantsch J; Institute for Clinical Microbiology and Hygiene, University Hospital Regensburg, 93053 Regensburg, Germany.
  • Wagner R; Institute for Clinical Microbiology and Hygiene, University Hospital Regensburg, 93053 Regensburg, Germany.
  • Schmidt B; Institute for Medical Microbiology and Hygiene, University of Regensburg, 93040 Regensburg, Germany.
  • Glück T; Institute for Clinical Microbiology and Hygiene, University Hospital Regensburg, 93053 Regensburg, Germany.
  • Gessner A; Kliniken Südostbayern AG, Klinikum Traunstein, 83278 Traunstein, Germany.
  • Peterhoff D; Institute for Clinical Microbiology and Hygiene, University Hospital Regensburg, 93053 Regensburg, Germany.
iScience ; 25(4): 104076, 2022 Apr 15.
Article in English | MEDLINE | ID: covidwho-1739821
ABSTRACT
SARS-CoV-2 Omicron is the first pandemic variant of concern exhibiting an abrupt accumulation of mutations particularly in the receptor-binding domain that is a critical target of vaccination induced and therapeutic antibodies. Omicron's mutations did only marginally affect the binding of ACE2, and the two antibodies Sotrovimab and CR3022 but strongly impaired the binding of Casirivimab and Imdevimab. Moreover, as compared with Wuhan, there is reduced serum reactivity and a pronounced loss of competitive surrogate virus neutralization (sVN) against Omicron in naïve vaccinees and in COVID-19 convalescents after infection and subsequent vaccination. Finally, although the booster vaccination response conferred higher titers and better sVN, the effect was nonetheless significantly lower compared with responses against Wuhan. Overall, our data suggest that the antigenicity of Omicrons receptor binding motive has largely changed but antibodies such as Sotrovimab targeting other conserved sites maintain binding and therefore hold potential in prophylaxis and treatment of Omicron-induced COVID-19.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines / Variants Language: English Journal: IScience Year: 2022 Document Type: Article Affiliation country: J.isci.2022.104076

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines / Variants Language: English Journal: IScience Year: 2022 Document Type: Article Affiliation country: J.isci.2022.104076